Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG: Apatinib Mesylate Tablets
DRUG: EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)

Sponsor

Peking University Third Hospital